Podcasts

Episode 41 | Decoding Perioperative Immunotherapy In NSCLC

This episode is hosted by: Dr Pei Ni Ding, Dr Samantha Bowyer, and Mr Naveed Alam.

Decoding Perioperative Immunotherapy In NSCLC

Episode Summary

In this TOGA podcast, we provide an overview of the recent neoadjuvant, adjuvant, and perioperative IO data, the options and considerations for treatment, and the current reimbursement landscape.

Show Hosts

This episode’s host are:

Dr Pei Ni Ding, Medical Oncologist from Westmead and Nepean Hospitals Sydney
Dr Samantha Bowyer, Medical Oncologist from Sir Charles Gairdner Hospital in Perth
Mr Naveed Alam, Thoracic Surgeon from St Vincents, Epworth and Monash in Melbourne

Show links

Many emerging treatments are discussed in this podcast, and clinicians are reminded that oncology access programs are listed in the medicines access portal.

Sponsor

This episode is proudly sponsored by MSD.

Play Episode 41 | Decoding Perioperative Immunotherapy In NSCLC

More Podcasts

75 – The Evolving Landscape of ROS1-positive NSCLC

Podcasts
September 4, 2026

Host A/Prof Steven Kao is joined by A/Prof Venessa Chin and Dr Ben Kong,

74 – Prof Zarnie Lwin OAM: Mentorship, Research, and the Future of Lung Cancer Treatment

Podcasts
August 28, 2026

Host A/Prof Mel Moore interviews Prof Zarnie Lwin OAM, University of Queensland; Medical Oncologist at Royal Brisbane and Women’s Hospital and The Prince Charles Hospital.

73 – Smoking Stigma and Lung Cancer Care in the Screening Era

Podcasts
August 14, 2026

A/Prof Gavin Wright sits down with a multidisciplinary panel of experts to tackle the critical and complex issue of smoking-related stigma in lung cancer.

72 – Dr Jazmin Eckhaus: Robotic Innovations and Ethics in Thoracic Surgery

Podcasts
July 31, 2026

Host A/Prof Mel Moore interviews Dr Jazmin Eckhaus, a practising surgeon in the subspecialty of thoracic surgery.

71 – Immunotherapy in Thoracic Cancers: Applying Broad IO Access Across Thoracic Malignancies

Podcasts
June 26, 2026

Host A/Prof Adnan Nagrial leads a panel discussing the clinical implications of the broad PBS listing of ipilimumab and nivolumab in Australia.

70 – Immunotherapy in Thoracic Cancers: From Indication-Based to Biology-Driven

Podcasts
June 19, 2026

Host A/Prof Deme Karikios leads a panel discussion focusing on the recent, groundbreaking broad PBS listing of certain immunotherapy agents in Australia.

Join our community – stay up to date with the latest research, TOGA news and events

The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

Contact

PO Box 1103
Thornbury VIC 3071
Ph: +61 3 9087 3550
ABN: 47 641 984 198

TOGA

Quicklinks

Thoracic Oncology Group of Australasia is registered with the Australian Taxation Office as an Income Tax Exempt Charitable Entity. Donations $2 and over are tax deductible.